Literature DB >> 34653748

Supportive care in multiple myeloma: Current practices and advances.

Teresa S Miceli1, Wilson I Gonsalves2, Francis K Buadi3.   

Abstract

Supportive care in multiple myeloma (MM) can have a major impact on quality of life and the survival outcomes of MM patients. In this review, we will focus on disease and treatment related toxicities experienced by MM patients and what are the best approaches to date to help mitigate the effects. We will specifically focus on a practical approach to managing bone disease, thrombosis, infection risk, peripheral neuropathy, dermatologic complications, gastrointestinal and ocular toxicities, and fatigue in MM.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Multiple myeloma; Quality of life; Supportive care

Mesh:

Year:  2021        PMID: 34653748      PMCID: PMC8688260          DOI: 10.1016/j.ctarc.2021.100476

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN: 2468-2942


  76 in total

1.  Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.

Authors:  Min Jung Lee; Paige Wickner; Laura Fanning; Robert Schlossman; Paul Richardson; Jacob Laubach; Maria Castells
Journal:  Br J Haematol       Date:  2014-05-14       Impact factor: 6.998

2.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.

Authors:  Ellen M Lavoie Smith; Herbert Pang; Constance Cirrincione; Stewart Fleishman; Electra D Paskett; Tim Ahles; Linda R Bressler; Camilo E Fadul; Chetaye Knox; Nguyet Le-Lindqwister; Paul B Gilman; Charles L Shapiro
Journal:  JAMA       Date:  2013-04-03       Impact factor: 56.272

3.  Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.

Authors:  Patrick Yau; Victor H Jimenez-Zepeda; Kyla Bailey; Peter Duggan; Jason Tay; Nizar J Bahlis; Paola Neri; Sylvia McCulloch
Journal:  Leuk Lymphoma       Date:  2019-06-13

4.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Authors:  Andrew L Himelstein; Jared C Foster; James L Khatcheressian; John D Roberts; Drew K Seisler; Paul J Novotny; Rui Qin; Ronald S Go; Stephen S Grubbs; Tracey O'Connor; Mario R Velasco; Douglas Weckstein; Ann O'Mara; Charles L Loprinzi; Charles L Shapiro
Journal:  JAMA       Date:  2017-01-03       Impact factor: 56.272

5.  A randomized trial of vertebroplasty for osteoporotic spinal fractures.

Authors:  David F Kallmes; Bryan A Comstock; Patrick J Heagerty; Judith A Turner; David J Wilson; Terry H Diamond; Richard Edwards; Leigh A Gray; Lydia Stout; Sara Owen; William Hollingworth; Basavaraj Ghdoke; Deborah J Annesley-Williams; Stuart H Ralston; Jeffrey G Jarvik
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

6.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

7.  Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.

Authors:  Deirdre R Pachman; Breanna L Weisbrod; Drew K Seisler; Debra L Barton; Kelliann C Fee-Schroeder; Thomas J Smith; Daniel H Lachance; Heshan Liu; Randy A Shelerud; Andrea L Cheville; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2014-09-24       Impact factor: 3.603

Review 8.  The new oral anticoagulants in clinical practice.

Authors:  Wilson I Gonsalves; Rajiv K Pruthi; Mrinal M Patnaik
Journal:  Mayo Clin Proc       Date:  2013-05       Impact factor: 7.616

Review 9.  Bortezomib-induced painful neuropathy in patients with multiple myeloma.

Authors:  Małgorzata Bilińska; Lidia Usnarska-Zubkiewicz; Anna Pokryszko-Dragan
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-11

10.  Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

Authors:  S K Kumar; A Dispenzieri; R Fraser; F Mingwei; G Akpek; R Cornell; M Kharfan-Dabaja; C Freytes; S Hashmi; G Hildebrandt; L Holmberg; R Kyle; H Lazarus; C Lee; J Mikhael; T Nishihori; J Tay; S Usmani; D Vesole; R Vij; B Wirk; A Krishnan; C Gasparetto; T Mark; Y Nieto; P Hari; A D'Souza
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.